Latest Insider Trading Transactions
Page: < prev 1 ... 661 662 663 664 665 666 667 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 29 2021 | TMCI | TREACE MEDICAL CON ... | TREACE JAMES T | Director | Option Exercise | C | 0.00 | 399,632 | 0 | 0 | |
Apr 29 2021 | TMCI | TREACE MEDICAL CON ... | TREACE JAMES T | Director | Option Exercise | J | 0.00 | 13,169 | 0 | 569,067 | |
Apr 29 2021 | TMCI | TREACE MEDICAL CON ... | TREACE JAMES T | Director | Option Exercise | J | 0.00 | 9,250 | 0 | 399,633 | |
Apr 29 2021 | TMCI | TREACE MEDICAL CON ... | TREACE JAMES T | Director | Buy | C | 0.00 | 569,067 | 0 | 1,478,946 | 909.9 K to 1.5 M (+62.54 %) |
Apr 29 2021 | TMCI | TREACE MEDICAL CON ... | TREACE JAMES T | Director | Buy | C | 0.00 | 399,633 | 0 | 2,205,258 | 1.8 M to 2.2 M (+22.13 %) |
Apr 29 2021 | TMCI | TREACE MEDICAL CON ... | BAYS F BARRY | Director | Option Exercise | C | 0.00 | 413,326 | 0 | 0 | |
Apr 29 2021 | TMCI | TREACE MEDICAL CON ... | BAYS F BARRY | Director | Option Exercise | J | 0.00 | 9,569 | 0 | 413,326 | |
Apr 29 2021 | TMCI | TREACE MEDICAL CON ... | BAYS F BARRY | Director | Buy | C | 0.00 | 413,326 | 0 | 1,728,293 | 1.3 M to 1.7 M (+31.43 %) |
Apr 29 2021 | TMCI | TREACE MEDICAL CON ... | Owens Daniel E. | Chief HR Officer | Buy | P | 17.00 | 4,000 | 68,000 | 4,000 | 0 to 4 K |
Apr 29 2021 | FSC | Oaktree Specialty ... | TANNENBAUM LEONARD M | 10% Owner | Sell | S | 6.78 | 94,052 | 637,748 | 21,430,365 | 21.5 M to 21.4 M (-0.44 %) |
Apr 29 2021 | FSC | Oaktree Specialty ... | TANNENBAUM LEONARD M | 10% Owner | Sell | S | 6.75 | 100,000 | 675,050 | 21,524,417 | 21.6 M to 21.5 M (-0.46 %) |
Apr 29 2021 | FSC | Oaktree Specialty ... | TANNENBAUM LEONARD M | 10% Owner | Sell | S | 6.73 | 194,130 | 1,307,427 | 21,624,417 | 21.8 M to 21.6 M (-0.89 %) |
Apr 29 2021 | CURO | CURO Group Holding ... | Gayhardt Donald | Chief Executive Off ... | Gift | G | 0.00 | 9,125 | 0 | 966,521 | 975.6 K to 966.5 K (-0.94 %) |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Option Exercise | M | 16.08 | 13,368 | 214,957 | 7,332 | |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Option Exercise | M | 8.21 | 14,662 | 120,375 | 6,038 | |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Option Exercise | M | 7.91 | 12,856 | 101,691 | 0 | |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Option Exercise | M | 7.91 | 36,127 | 285,765 | 12,856 | |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Option Exercise | M | 7.91 | 11,017 | 87,144 | 48,983 | |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Sell | S | 25.04 | 40,886 | 1,023,589 | 0 | 40.9 K to 0 (-100.00 %) |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Buy | M | 16.08 | 13,368 | 214,957 | 40,886 | 27.5 K to 40.9 K (+48.58 %) |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Buy | M | 8.21 | 14,662 | 120,375 | 27,518 | 12.9 K to 27.5 K (+114.05 %) |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Buy | M | 7.91 | 12,856 | 101,691 | 12,856 | 0 to 12.9 K |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Sell | S | 25.65 | 507 | 13,005 | 0 | 507 to 0 (-100.00 %) |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Sell | S | 25.54 | 10,000 | 255,387 | 507 | 10.5 K to 507 (-95.17 %) |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Sell | S | 25.25 | 15,000 | 378,783 | 10,507 | 25.5 K to 10.5 K (-58.81 %) |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Sell | S | 25.50 | 10,620 | 270,810 | 25,507 | 36.1 K to 25.5 K (-29.40 %) |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Buy | M | 7.91 | 36,127 | 285,765 | 36,127 | 0 to 36.1 K |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Sell | S | 25.79 | 11,017 | 284,163 | 0 | 11 K to 0 (-100.00 %) |
Apr 29 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Buy | M | 7.91 | 11,017 | 87,144 | 11,017 | 0 to 11 K |
Apr 29 2021 | CHEF | Chefs' Warehouse, ... | Pappas John | Vice Chairman | Sell | S | 33.00 | 300 | 9,900 | 758,128 | 758.4 K to 758.1 K (-0.04 %) |
Apr 29 2021 | CHEF | Chefs' Warehouse, ... | Pappas John | Vice Chairman | Sell | S | 32.06 | 56,973 | 1,826,554 | 758,428 | 815.4 K to 758.4 K (-6.99 %) |
Apr 29 2021 | CHEF | Chefs' Warehouse, ... | Pappas John | Vice Chairman | Sell | S | 31.55 | 33,595 | 1,059,922 | 815,401 | 849 K to 815.4 K (-3.96 %) |
Apr 29 2021 | CHEF | Chefs' Warehouse, ... | Pappas John | Vice Chairman | Sell | S | 35.30 | 13,034 | 460,100 | 848,996 | 862 K to 849 K (-1.51 %) |
Apr 29 2021 | CHEF | Chefs' Warehouse, ... | Pappas John | Vice Chairman | Sell | S | 34.54 | 37,395 | 1,291,623 | 862,030 | 899.4 K to 862 K (-4.16 %) |
Apr 29 2021 | CHEF | Chefs' Warehouse, ... | Pappas John | Vice Chairman | Sell | S | 33.15 | 27,161 | 900,387 | 899,425 | 926.6 K to 899.4 K (-2.93 %) |
Apr 29 2021 | CHEF | Chefs' Warehouse, ... | Pappas John | Vice Chairman | Sell | S | 32.80 | 81,971 | 2,688,649 | 926,586 | 1 M to 926.6 K (-8.13 %) |
Apr 29 2021 | CHEF | Chefs' Warehouse, ... | Pappas John | Vice Chairman | Sell | S | 35.14 | 49,571 | 1,741,925 | 1,008,557 | 1.1 M to 1 M (-4.68 %) |
Apr 29 2021 | IMPL | IMPEL NEUROPHARMA ... | 5AM Ventures V, L.P. | 10% Owner | Option Exercise | C | 13.50 | 1,359,799 | 18,357,287 | 0 | |
Apr 29 2021 | IMPL | IMPEL NEUROPHARMA ... | 5AM Ventures V, L.P. | 10% Owner | Option Exercise | C | 0.00 | 5,876,034 | 0 | 0 | |
Apr 29 2021 | IMPL | IMPEL NEUROPHARMA ... | 5AM Ventures V, L.P. | 10% Owner | Option Exercise | C | 0.00 | 8,201,930 | 0 | 0 | |
Apr 29 2021 | IMPL | IMPEL NEUROPHARMA ... | 5AM Ventures V, L.P. | 10% Owner | Option Exercise | C | 0.00 | 8,845,942 | 0 | 0 | |
Apr 29 2021 | IMPL | IMPEL NEUROPHARMA ... | 5AM Ventures V, L.P. | 10% Owner | Option Exercise | C | 0.00 | 13,233,885 | 0 | 0 | |
Apr 29 2021 | IMPL | IMPEL NEUROPHARMA ... | 5AM Ventures V, L.P. | 10% Owner | Buy | P | 15.00 | 575,000 | 8,625,000 | 575,000 | 0 to 575 K |
Apr 29 2021 | IMPL | IMPEL NEUROPHARMA ... | 5AM Ventures V, L.P. | 10% Owner | Buy | C | 13.50 | 101,457 | 1,369,670 | 2,309,791 | 2.2 M to 2.3 M (+4.59 %) |
Apr 29 2021 | IMPL | IMPEL NEUROPHARMA ... | 5AM Ventures V, L.P. | 10% Owner | Buy | C | 0.00 | 358,878 | 0 | 2,208,334 | 1.8 M to 2.2 M (+19.40 %) |
Apr 29 2021 | IMPL | IMPEL NEUROPHARMA ... | 5AM Ventures V, L.P. | 10% Owner | Buy | C | 0.00 | 500,932 | 0 | 1,849,456 | 1.3 M to 1.8 M (+37.15 %) |
Apr 29 2021 | IMPL | IMPEL NEUROPHARMA ... | 5AM Ventures V, L.P. | 10% Owner | Buy | C | 0.00 | 540,265 | 0 | 1,348,524 | 808.3 K to 1.3 M (+66.84 %) |
Apr 29 2021 | IMPL | IMPEL NEUROPHARMA ... | 5AM Ventures V, L.P. | 10% Owner | Buy | C | 0.00 | 808,259 | 0 | 808,259 | 0 to 808.3 K |
Apr 29 2021 | MDVX | H-CYTE, INC. | Horne William E | Director | Option Exercise | J | 0.01 | 1,869,667 | 26,175 | 1,869,667 | |
Apr 29 2021 | MDVX | H-CYTE, INC. | Horne William E | Director | Option Exercise | J | 0.00 | 3,655,382 | 0 | 3,655,382 | |
Apr 29 2021 | SNOW | Snowflake Inc. | Dageville Benoit | President of Produc ... | Sell | S | 238.05 | 1,206 | 287,093 | 6,024,324 | 6 M to 6 M (-0.02 %) |
Apr 29 2021 | SNOW | Snowflake Inc. | Dageville Benoit | President of Produc ... | Sell | S | 237.19 | 22,781 | 5,403,494 | 6,025,530 | 6 M to 6 M (-0.38 %) |
Apr 29 2021 | SNOW | Snowflake Inc. | Dageville Benoit | President of Produc ... | Sell | S | 236.51 | 37,377 | 8,840,184 | 6,048,311 | 6.1 M to 6 M (-0.61 %) |
Apr 29 2021 | SNOW | Snowflake Inc. | Dageville Benoit | President of Produc ... | Gift | G | 0.00 | 8,925 | 0 | 6,085,688 | 6.1 M to 6.1 M (-0.15 %) |
Apr 29 2021 | TPGH | Accel Entertainmen ... | Rubenstein Andrew H. | CEO and President | Sell | S | 13.25 | 6,949 | 92,058 | 4,151,283 | 4.2 M to 4.2 M (-0.17 %) |
Apr 29 2021 | TPGH | Accel Entertainmen ... | Rubenstein Andrew H. | CEO and President | Sell | S | 13.10 | 34,000 | 445,451 | 4,158,232 | 4.2 M to 4.2 M (-0.81 %) |
Apr 29 2021 | TPGH | Accel Entertainmen ... | Rubenstein Andrew H. | CEO and President | Sell | S | 13.01 | 9,051 | 117,772 | 4,192,232 | 4.2 M to 4.2 M (-0.22 %) |
Apr 29 2021 | LLY | ELI LILLY & Co | Zakrowski Donald A | Chief Accounting Of ... | Sell | S | 181.38 | 3,000 | 544,140 | 5,987 | 9 K to 6 K (-33.38 %) |
Apr 29 2021 | TRHC | Tabula Rasa Health ... | Speers Andrea Carolan | Chief Accounting Of ... | Grant | A | 0.00 | 2,060 | 0 | 63,546 | 61.5 K to 63.5 K (+3.35 %) |
Apr 29 2021 | SQ | Square, Inc. | Whiteley Sivan | Gen. Counsel & Corp ... | Option Exercise | A | 253.79 | 26,497 | 6,724,674 | 26,497 |